Intel Available For Sale Securities Debt Securities Current decreased by 32.9% to $15.54B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 28.4%, from $12.10B to $15.54B. Over 5 years (FY 2020 to FY 2025), Available For Sale Securities Debt Securities Current shows an upward trend with a 58.8% CAGR.
An increase suggests higher liquidity and a conservative cash management strategy, while a decrease may indicate cash deployment for operations or acquisitions.
This represents the portion of a company's investment portfolio consisting of debt securities that are expected to be so...
Common among large-cap pharmaceutical firms maintaining significant cash reserves for R&D and M&A activities.
current_assets_available_for_sale_securities_debt_securi_87ec82| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.01B | $4.00B | $24.43B | $32.48B | $22.65B | $18.03B | $17.19B | $19.30B | $15.91B | $17.41B | $17.96B | $14.39B | $17.99B | $15.30B | $13.81B | $12.10B | $11.56B | $19.79B | $23.15B | $15.54B |
| QoQ Change | — | +32.8% | +510.0% | +33.0% | -30.3% | -20.4% | -4.6% | +12.3% | -17.6% | +9.4% | +3.1% | -19.9% | +25.0% | -14.9% | -9.7% | -12.4% | -4.4% | +71.2% | +17.0% | -32.9% |
| YoY Change | — | — | — | — | +651.6% | +350.3% | -29.6% | -40.6% | -29.8% | -3.4% | +4.4% | -25.5% | +13.1% | -12.1% | -23.1% | -15.9% | -35.7% | +29.4% | +67.6% | +28.4% |